Calcium-activated potassium channels - a therapeutic target for modulating nitric oxide in cardiovascular disease?
about
Calcium and electrical signalling along endothelium of the resistance vasculaturePulmonary hypertension in wild type mice and animals with genetic deficit in KCa2.3 and KCa3.1 channels.Down-regulation of KCa2.3 channels causes erectile dysfunction in miceThe activation effect of hainantoxin-I, a peptide toxin from the Chinese spider, Ornithoctonus hainana, on intermediate-conductance Ca2+-activated K+ channels.New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1.Hyperhomocysteinemia impairs endothelium-derived hyperpolarizing factor-mediated vasorelaxation in transgenic cystathionine beta synthase-deficient miceSingle atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertensionInhibition of Myogenic Tone in Rat Cremaster and Cerebral Arteries by SKA-31, an Activator of Endothelial KCa2.3 and KCa3.1 Channels.Tuning electrical conduction along endothelial tubes of resistance arteries through Ca(2+)-activated K(+) channelsSKA-31, a novel activator of SK(Ca) and IK(Ca) channels, increases coronary flow in male and female rat heartsEffects of exercise and L-arginine intake on inflammation in aorta of high-fat diet induced obese ratsDevelopment of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators.Calycosin and Formononetin Induce Endothelium-Dependent Vasodilation by the Activation of Large-Conductance Ca2+-Activated K+ Channels (BKCa).Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.Role of the potassium channel KCa3.1 in diabetic nephropathy.Calcium-activated potassium channels in ischemia reperfusion: a brief update.Therapeutic strategies for endothelial dysfunction.Preserved regulation of renal perfusion pressure by small and intermediate conductance KCa channels in hypertensive mice with or without renal failure.
P2860
Q27025903-4609055E-5346-45F2-8B22-14C17D5B23F0Q33654786-BCC69F2C-6D0E-45AF-922D-B1C121120B4AQ33812566-7BA637A2-2C05-4A70-91A1-50F92257CF00Q34101834-88A597EE-2361-4188-8E4E-574758162FDAQ34125233-A14EE365-8354-4F09-8E66-6AA108C48A2CQ35172506-D2CE553D-0AC6-4514-A144-FEDEA6FC4FB9Q35748944-B3A8251D-636B-4789-B6CE-69E4618F2DB1Q35847147-8FB3A44E-9785-4D7C-B228-EE46E7C11D26Q36307734-F7F29761-0974-401B-82DB-4931C9E0B747Q36529014-76C5621C-2F78-4823-BF37-BE13DC40FC7FQ36986534-799D2A22-E564-4DC1-A088-CFAA99B1EDC2Q37409003-0637B246-92D5-4EC2-ADA4-9DDD1995019FQ37479253-54E7D10E-23AB-4E71-A4DF-8F078C41327EQ38056312-95EA7BE2-3805-4986-B6E7-A90F75A5D762Q38223110-5E841F4A-66C0-4388-8436-D4815A8B98F0Q38262120-35EE6E63-3AE6-4B4B-B0D4-8E839CF50047Q46470925-3AB812EC-9B4D-46E2-9A18-9AA5ED7C0181Q51135816-0E982310-7DB9-4EB1-BA5E-34A9B042C03B
P2860
Calcium-activated potassium channels - a therapeutic target for modulating nitric oxide in cardiovascular disease?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Calcium-activated potassium ch ...... ide in cardiovascular disease?
@en
Calcium-activated potassium ch ...... ide in cardiovascular disease?
@nl
type
label
Calcium-activated potassium ch ...... ide in cardiovascular disease?
@en
Calcium-activated potassium ch ...... ide in cardiovascular disease?
@nl
prefLabel
Calcium-activated potassium ch ...... ide in cardiovascular disease?
@en
Calcium-activated potassium ch ...... ide in cardiovascular disease?
@nl
P2093
P2860
P1476
Calcium-activated potassium ch ...... ide in cardiovascular disease?
@en
P2093
Christel Kroigaard
Thomas Dalsgaard
Ulf Simonsen
P2860
P304
P356
10.1517/14728222.2010.500616
P407
P577
2010-08-01T00:00:00Z